Vogt-Koyanagi-Harada Disease Clinical Trials
2 recruiting trials for Vogt-Koyanagi-Harada Disease. Eligibility criteria explained in plain English.
TrialFinderData lists 2 Vogt-Koyanagi-Harada Disease clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Research is led by Tianjin Medical University (1), University of Sao Paulo (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Adalimumab (drug, 1 trial), followed by Early high-dose corticosteroid and immunosuppressive therapy.
Track Vogt-Koyanagi-Harada Disease trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
A Study of Adalimumab in Acute Vogt-Koyanagi-Harada Disease
This project is designed to test the hypothesis that adalimumab is clinically useful for patients with acuta Vogt-Koyanagi-Harada disease
Early Immunosuppressive Therapy on the Course of Vogt-Koyanagi-Harada Disease
This prospective study will include patients with Vogt-Koyanagi-Harada disease from disease onset, treated with early systemic high-dose corticosteroid and immunosuppressive...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Vogt-Koyanagi-Harada Disease, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Vogt-Koyanagi-Harada Disease, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Vogt-Koyanagi-Harada Disease, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.